DRUG
Linaclotide or Matching Placebo
Linaclotide or Matching Placebo, administered orally, once daily, for the duration of the trial
Status
Completed
Phase
Phase 3
Enrollment
805
Locations
107
Results
Posted
Publications
2
Study summary
The purpose of this study is to determine the safety and efficacy of linaclotide administered to patients with Irritable Bowel Syndrome with Constipation (IBS-C).
Interventions
DRUG
Linaclotide or Matching Placebo, administered orally, once daily, for the duration of the trial
Timeline
First posted
Jul 14, 2009
Study start
Jul 2009
Primary completion
Sep 2010
Study completion
Sep 2010
Results posted
Jan 30, 2013
Registry updated
Nov 5, 2013
Outcomes
Abdominal Pain and Complete Spontaneous Bowel Movement (APC) Responder, 9 Out of 12 Weeks
Time frame · Change from Baseline to Week 12
A patient is considered to be a 9 out of 12 week APC responder if, for at least 9 out of the first 12 weeks of the treatment period, the patient had at least 3 CSBMs, had an increase of at least 1 CSBM from baseline, and had a decrease of at least 30 percent in their Abdominal Pain (AP) score from baseline during a particular week. The AP score assesses patient's worst AP in the past 24 hours using an 11-point scale (from 0-10), where 0 represents no AP and 10 represents very severe AP. SBM is defined as a bowel movement that occurs in the absence of laxative, enema, or suppository use on either the calendar day of the bowel movement or the calendar day before the bowel movement. CSBM is defined as an SBM associated with a sense of complete evacuation.
Complete Spontaneous Bowel Movement (CSBM) 3+1 Responder, 9 Out of 12 Weeks
Time frame · Change from Baseline to Week 12
A patient is considered to be a CSBM 3+1 responder if, for at least 9 out of the 12 weeks of the treatment period, the patient had at least 3 CSBMs and experienced an increase of at least 1 CSBM from baseline during a particular week. A CSBM was defined as a Spontaneous Bowel Movement (SBM) that was associated with a sense of complete evacuation. An SBM was defined as a bowel movement (BM) that occurred in the absence of laxative, enema, or suppository use on either the calendar day of the BM or the calendar day before the BM.
Abdominal Pain Responder, 9 Out of 12 Weeks
Time frame · Change from Baseline to Week 12
A patient is considered to be an abdominal pain responder if, for at least 9 out of the 12 weeks of the treatment period, they experienced a decrease of at least 30 percent in the mean abdominal pain score from baseline during a particular week. The Abdominal Pain score assesses patient's worst abdominal pain in the past 24 hours using an 11-point scale (from 0-10), where 0 represents no abdominal pain and 10 represents very severe abdominal pain.
Abdominal Pain and Complete Spontaneous Bowel Movement (APC) Responder, 6 Out of 12 Weeks
Time frame · Change from Baseline to Week 12
A patient is considered to be a 6 out of 12 week APC responder if, for at least 6 out of the first 12 weeks of the treatment period, the patient had an increase of at least 1 CSBM from baseline, and had a decrease of at least 30 percent in their Abdominal Pain (AP) score from baseline during a particular week. The AP score assesses patient's worst AP in the past 24 hours using an 11-point scale (from 0-10), where 0 represents no AP and 10 represents very severe AP. SBM is defined as a bowel movement that occurs in the absence of laxative, enema, or suppository use on either the calendar day of the bowel movement or the calendar day before the bowel movement. CSBM is defined as an SBM associated with a sense of complete evacuation.
12-Week Complete Spontaneous Bowel Movement (CSBM) Frequency
Time frame · Change from Baseline to Week 12
The change from baseline in 12-week CSBM frequency (i.e., weekly CSBM frequency over the first 12 weeks of the Treatment Period).
12-Week Spontaneous Bowl Movement (SBM) Frequency
Time frame · Change from Baseline to Week 12
The change from baseline in 12-week SBM frequency (i.e., weekly SBM frequency over the first 12 weeks of the Treatment Period).
12-Week Change in Stool Consistency
Time frame · Change from Baseline to Week 12
The consistency of each BM was assessed by patients using the 7-point Bristol Stool Form Scale (BSFS) from 1 to 7. 1. = separate hard lumps like nuts \[difficult to pass\] 2. = sausage shaped but lumpy 3. = like a sausage but with cracks on surface 4. = like a sausage or snake, smooth and soft 5. = soft blobs with clear-cut edges \[passed easily\] 6. = fluffy pieces with ragged edges, a mushy stool 7. = watery, no solid pieces \[entirely liquid\]).
12-Week Change in Severity of Straining
Time frame · Change from Baseline to Week 12
Straining is measured on a 5-point scale where a value of 1 is "not at all" and a value of 5 is "an extreme amount".
12-Week Change in Abdominal Pain Score
Time frame · Change from Baseline to Week 12
Abdominal Pain at its worst (in the last 24 hours) is based on an 11-point scale where 0 represents no abdominal pain and 10 represents very severe abdominal pain.
12-Week Change in Abdominal Discomfort
Time frame · Change from Baseline to Week 12
Abdominal discomfort was assessed on an 11-point scale where a value of 0 is "none" and a value of 10 is "very severe".
12-Week Change in Bloating
Time frame · Change from Baseline to Week 12
Bloating was assessed on an 11-point scale where a value of 0 is "none" and a value of 10 is "very severe".
Complete Spontaneous Bowl Movement (CSBM) Responder for 6 Weeks Out of 12 Weeks of Treatment
Time frame · Change from Baseline to Week 12
A patient is considered to be a CSBM responder if, for at least 6 out of the 12 weeks of the treatment period, an increase of at least 1 CSBM per week from baseline was experienced.
Abdominal Pain Responder for 6 Out of 12 Weeks
Time frame · Change from Baseline to Week 12
A patient is considered to be an AP responder if, for at least 6 out of the first 12 weeks of the treatment period, the patient had a decrease of at least 30 percent in their Abdominal Pain score from baseline during a particular week.
12-Week Percent of Abdominal Pain-free Days
Time frame · Change from Baseline to Week 12
Abdominal pain free (APF) days are those days where the patient reported a score of '0' for abdominal pain at its worst. Abdominal Pain at its worst (in the last 24 hours) is based on an 11-point scale where 0 represents no abdominal pain and 10 represents very severe abdominal pain.
Eligibility
Inclusion Criteria: * Patient has completed a colonoscopy according to the AGA criteria, with no clinically significant findings * Patient has successfully completed protocol procedures (with no clinically significant findings): physical exam, 12-lead ECG, or clinical laboratory tests * Patient meets protocol criteria for diagnosis of IBS-C * Patient demonstrates continued IBS-C through Pretreatment Period * Patient is compliant with IVRS Exclusion Criteria: * Patient has history of loose or watery stools * Patient has symptoms of or been diagnosed with a medical condition that may contribute to abdominal pain * Patient has a structural abnormality of the gastrointestinal (GI) tract or a disease or condition that can affect GI motility * Patient has any protocol-excluded or clinically significant medical or surgical history that could confound the study assessments
Study locations
United States. Showing up to 24 locations stored in the fast local snapshot.
Ironwood Investigational Site
Birmingham, Alabama, United States
Ironwood Investigational Site
Huntsville, Alabama, United States
Ironwood Investigational Site
Phoenix, Arizona, United States
Ironwood Investigational Site
Tempe, Arizona, United States
Ironwood Investigational Site
Tucson, Arizona, United States
Ironwood Investigational Site
Tucson, Arizona, United States
Ironwood Investigational Site
Sherwood, Arkansas, United States
Ironwood Investigational Site
Anaheim, California, United States
Ironwood Investigational Site
Chula Vista, California, United States
Ironwood Investigational Site
Encinitas, California, United States
Ironwood Investigational Site
Garden Grove, California, United States
Ironwood Investigational Site
Laguna Hills, California, United States
Ironwood Investigational Site
Orange, California, United States
Ironwood Investigational Site
San Carlos, California, United States
Ironwood Investigational Site
San Diego, California, United States
Ironwood Investigational Site
San Diego, California, United States
Ironwood Investigational Site
San Diego, California, United States
Ironwood Investigational Site
Colorado Springs, Colorado, United States
Ironwood Investigational Site
Bristol, Connecticut, United States
Ironwood Investigational Site
Boynton Beach, Florida, United States
Ironwood Investigational Site
Hollywood, Florida, United States
Ironwood Investigational Site
Inverness, Florida, United States
Ironwood Investigational Site
Jacksonville, Florida, United States
Ironwood Investigational Site
Jacksonville, Florida, United States
Publications
Related trials
Mayo Clinic · Irritable Bowel Syndrome With Constipation
Not applicable
Recruiting
65
2026-07
Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University · Colorectal Adenoma · Stage 0 Colorectal Cancer AJCC v8
Phase 2
Active, not recruiting
150
2026-07
AbbVie · Functional Constipation (FC) · Chronic Idiopathic Constipation (CIC)
Phase 3
Completed
123
2026-05
University of Nottingham · Cystic Fibrosis (CF)
Early Phase 1
Recruiting
26
2026-05
University of Wisconsin, Madison · Barrett Esophagus · Gastroesophageal Reflux Disease
Phase 1
Completed
43
2026-04
Texas Tech University Health Sciences Center, El Paso · Chronic Constipation · Diabete Mellitus
Phase 4
Active, not recruiting
23
2026-04
Md Mehedi Shahriar · Chronic Idiopathic Constipation · Irritable Bowel Syndrome (IBS-C)
Phase 4
Not yet recruiting
90
2026-02
University of Florida · Patients Scheduled for Colonoscopy
Phase 1 / Phase 2
Recruiting
10
2026-01
Related PeptideStat pages
Research pages describe evidence. Vendor pages, where available, describe independently tracked research-product listings and are not clinical recommendations.